Extract, Body Fluid, Or Cellular Material Of Undetermined Constitution Derived From Animal Is Active Ingredient Patents (Class 424/520)
  • Patent number: 10406205
    Abstract: A method of treating diabetes can include administering a therapeutically effective amount of a composition comprising a soluble protein fraction obtained from epidermal gel secretions of catfish to a patient in need thereof. The soluble protein fraction can include soluble proteins and lipids from the epidermal gel secretions of catfish. The soluble protein fraction can include about 87% of the soluble proteins and about 13% of the lipids. The composition can be administered by intraperitoneal (IP) or sub-cutaneous (SC) injection.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 10, 2019
    Inventor: Jassim M. Hassan M. Ali
  • Patent number: 10385314
    Abstract: A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating a population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 20, 2019
    Assignee: EXOSTEM BIOTEC LTD.
    Inventors: Chaya Brodie, Shlomit Brodie
  • Patent number: 10377794
    Abstract: Herein is reported a method for the purification of an antibody directly captured from clarified cell culture supernatants using Streamline CST and/or Capto MMC, wherein especially product related (aggregates and fragments) and process related impurities (host cell protein, media components) could efficiently be removed, resulting in a preparation with a purity comparable to classical protein A affinity chromatography.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 13, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Thorsten Lemm, Markus Strasser, Hidenari Yamada
  • Patent number: 10344260
    Abstract: The present invention relates to novel melanocytes and melanoblasts. In addition, the present invention relates to a novel method for producing melanocytes and melanoblasts. Specifically, provided is novel melanocytes of which gene expression, melanin content, and tyrosinase activity are different from those of conventional melanocytes. Even more specifically, provided is novel melanoblasts of which the gene expression, the melanin content the tyrosinase activity, and the protein expression are different from those of conventional melanocytes. Additionally, provided is a novel method for producing melanocytes or melanoblasts by culturing keratinocytes.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: July 9, 2019
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Eun Gyung Cho, Bum Ho Bin, Tae Ryong Lee, Ji Yeon Han, Hyun Jung Choi
  • Patent number: 10328122
    Abstract: A method of treating fulminant hepatic failure in a subject, includes administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a DLL4 cytokine. A method of treating liver failure, sub-acute liver failure, chronic liver failure or acute-on-chronic liver failure in a subject, includes administering an therapeutically effective amount of a DLL4 cytokine to the subject.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: June 25, 2019
    Assignee: Zhejiang University
    Inventors: Jun Li, Lanjuan Li, Xin Chen, Jiang Li
  • Patent number: 10265345
    Abstract: The present invention provides a method for treatment of acute cerebrovascular diseases, and also provides the use of the extracts from rabbit skin inflamed by vaccinia virus in the manufacture of a medicament for treatment of acute cerebrovascular diseases.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: April 23, 2019
    Assignee: Vanworld Pharmaceutical (Rugao) Co., Ltd.
    Inventor: Mansang Lau
  • Patent number: 10261068
    Abstract: The methods disclosed herein relate to an improved tool incorporating platelet count into a multi-biomarker based outcome risk stratification model for evaluating mortality risk in pediatric patients having sepsis. The methods described here are useful for treating sepsis, for point of care clinical decision support, for stratifying septic shock patients based on baseline mortality risk, and for clinical trial design, among other uses.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 16, 2019
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventor: Hector R. Wong
  • Patent number: 10251833
    Abstract: Described herein are compositions that contract and reduce pore size. The compositions of the disclosure are also useful for collagen contraction of the skin, calming skin, and reducing oil on the skin. The compositions comprise cosmetic ingredients such as glycerin; cyclopentasiloxane; polysilicone-11; pentaerythrityl tetraethylhexanoate; dipropylene glycol; methyl methacrylate crosspolymer; betaine; bis-PEG/PPG-16/PPG-16/16 PEG/16 dimethicone; Albizia julibrissin bark extract; Evodia rutaecarpa fruit extract; hydrolyzed soy flour; sea whip extract; and a dermatologically acceptable vehicle.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 9, 2019
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Geetha Kalahasti, Lisha Van Pelt
  • Patent number: 10227290
    Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 12, 2019
    Assignees: The Regents of the University of California, President and Fellows of Harvard College
    Inventors: Michael A. Fischbach, Jeffrey A. Bluestone, Cristina Penaranda, Laura Brown, Jon Clardy
  • Patent number: 10172707
    Abstract: Tubular prostheses are provided for use in airways, upper digestive, and urinary tracts. Each of these uses has its own specific sets of biological specifications, based on what it must contain and exclude and the physical and chemical pressures and stresses to which it is subjected. The prostheses may be made from allogeneic cells. Thus they can be manufactured and stored prior to an individual's personal need arising.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 8, 2019
    Assignees: Humacyte, Inc., Yale University
    Inventors: Laura Niklason, Angela Huang, Liping Zhao, Shannon Dahl
  • Patent number: 10149874
    Abstract: A method is provided for treating a seaweed extract having a target molecule and a pyrogenic agent. The method includes inactivating the pyrogenic agent and/or removing the pyrogenic agent. The method results in a reduction in pyrogenicity of the extract. The method is useful in the preparation of pharmaceutical compositions and biomaterials for which pyrogen removal is critical.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 11, 2018
    Assignee: MARINOVA PTY LTD
    Inventors: Charles Dragar, Janet Helen Fitton, Vicki-Anne Gardiner, Damien Stringer, Samuel Karpiniec
  • Patent number: 10132805
    Abstract: A method for determining the amount of specific analyte of a sample which may show interferences by photometric assays, wherein the analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific reagents. Multiple calibration curves are generated for multiple wavelengths for the specific analyte. An interference test is performed simultaneously to the determination of the specific analyte, for quantifying the amount of interfering substances present in the sample. The amount of each interfering substances is compared to predetermined cut-off values. The optical signal for the specific analyte is measured in the reaction mixture at multiple wavelengths over the complete reaction time, and a calibration curve is selected depending on the interfering substances. The amount of specific analyte is quantified by comparison with the selected calibration curve for the chosen wavelengths.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: November 20, 2018
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Kurz, Eloisa Lopez-Calle
  • Patent number: 10111823
    Abstract: Shaving cream formulations can extend the life of shaving blades.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 30, 2018
    Assignee: GETCO LLC
    Inventors: Michael R. Cure, Peter Curtis
  • Patent number: 10058632
    Abstract: A placental construct is provided. The placental construct includes a therapeutically effective amount of human birth tissue material and a nanoparticle composition. Methods of treatment with the placental construct and a corresponding kit are also provided.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: August 28, 2018
    Assignee: Brahm Holdings, LLC
    Inventor: Timothy R. Brahm
  • Patent number: 9956246
    Abstract: A solid composition comprising the following components (A) and (B): (A) from 20 to 65 mass % of a fat globule membrane component; and (B) from 0.2 to 4 mass % of a water-soluble dietary fiber having a weight average molecular weight of 10,000 or more.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 1, 2018
    Assignee: KAO CORPORATION
    Inventors: Yuki Ishida, Youichi Arai, Yasushi Shioya
  • Patent number: 9943553
    Abstract: To provide a method for producing an oyster meat essence that more amply incorporates an antioxidant substance with high ORAC value as follows. A portion of an oyster meat extract more amply incorporating an antioxidant substance with high ORAC value is selected. An extraction method that allows incorporating further large amount of antioxidant substance with high ORAC value is employed. The beneficial oyster meat extract can be efficiently extracted in large amounts. Object An oyster meat is stored in an extraction container where water is accumulated. An oyster meat essence is extracted to generate an extract liquid. The extract liquid is injected to a centrifuge, and concurrently the centrifuge is rotated at a centrifugal acceleration where an antioxidant substance with high antioxidative potency and ORAC value is separated and removed from the extract liquid. The antioxidant substance with higher antioxidative potency and ORAC value is separated.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 17, 2018
    Assignee: WATANABE OYSTER LABORATORY CO., LTD.
    Inventors: Mitsugu Watanabe, Takayuki Watanabe, Hideaki Watanabe
  • Patent number: 9931361
    Abstract: The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing. In one embodiment, the composition is composed of one or more metazoan parasites or a mimic thereof sufficient to promote helminth-induced type-2 immune response. Preferably, the composition contains N. brasiliensis excretory/secretory antigen (NES) or an immune triggering portion thereof. The invention also relates to a method of accelerating wound healing in a subject in need of such treatment.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 3, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: William C. Gause, Fei Chen, Zhugong Liu, Pankaj Mishra
  • Patent number: 9879042
    Abstract: Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: January 30, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Alice L. Yu, Kun-Hsien Lin, Tai-Na Wu
  • Patent number: 9840627
    Abstract: The present invention provides application of camptothecin and derivatives thereof as antifouling agent, relating to camptothecin. Application of camptothecin and derivatives thereof as antifouling agent for facilities in water is provided, wherein the antifouling agent contains camptothecin and/or at least one of its derivatives. The application of camptothecin and derivatives thereof as antifouling agent for facilities in water can be used to prevent attachment of marine or freshwater micro-fouling organisms and/or large fouling organisms to the surfaces of facilities in the sea, lake, river or pool. The antifouling agent may also be used in mixture with other antifouling substance. Antifouling method for artificial facilities in water is provided. An antifouling paint for facilities in water is provided. Camptothecin and its derivatives have significant inhibitory activity to the attachment of fouling organisms, i.e.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: December 12, 2017
    Assignee: Xiamen University
    Inventors: Danqing Feng, Caihuan Ke, Wei Wang, Xiang Wang, Jian He, Hui Liu
  • Patent number: 9789224
    Abstract: Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: October 17, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Karen Christman, Jennifer Singelyn, Jessica Dequach
  • Patent number: 9782476
    Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 10, 2017
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Alice L. Yu, Kun-Hsien Lin, Tai-Na Wu
  • Patent number: 9759728
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods and kits for determining the human sperm quality.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: September 12, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Droit et de la Sante de Lille 2, Centre Hospitalier Regional Universitaire de Lille
    Inventors: Nicolas Sergeant, Valerie Mitchell, Fanny Jumeau, Julien Sigala
  • Patent number: 9713637
    Abstract: The invention provides an isolated Bacillus cereus sensu lato strain, selected from Bacillus anthracis, Bacillus cereus and Bacillus thuringiensis, in which the htrA gene or any part thereof is silenced, and vaccines comprising the same.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: July 25, 2017
    Assignee: State of Israel Prime Minister's Office Israel Institute for Biological Research
    Inventors: Ofer Cohen, Theodor Chitlaru, Avigdor Shafferman
  • Patent number: 9707258
    Abstract: The present invention relates to the use of a Bifidobacterium strain for the preparation of compositions, in particular of an infant formula, intended for the prevention and/or treatment of allergic-type manifestations. These compositions are obtained from a Bifidobacterium culture, without hydrolyzing milk proteins. The bacteria, which preferably belong to the species Bifidobacterium breve, may be killed or removed from the composition during the process.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: July 18, 2017
    Assignee: Compagnie Gervais Danone
    Inventors: Cécile Aubert-Jacquin, Francis Lecroix, Emmanuel Perrin, Valérie Petay
  • Patent number: 9694109
    Abstract: A placental construct is provided. The placental construct includes a therapeutically effective amount of human birth tissue material and a nanoparticle composition. Methods of treatment with the placental construct and a corresponding kit are also provided.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 4, 2017
    Assignee: Brahm Holdings, LLC
    Inventor: Timothy R. Brahm
  • Patent number: 9676838
    Abstract: Use of a nutritional supplement for increasing the bacterial mass in the rumen of a ruminant. The nutritional supplement includes proteins with a degree of hydrolysis above 28% and has more than 23 mg ?-amino nitrogen per gram of protein. The hydrolyzed proteins are preferably hemoglobin.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: June 13, 2017
    Assignee: APC EUROPE S.A.
    Inventors: Francisco Javier Polo Pozo, Carmen Rodriguez Canel, Alejandro Bach Ariza, Anna Aris Giralt
  • Patent number: 9642817
    Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: May 9, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Marcelle Machluf, Tomer Bronshtein
  • Patent number: 9629880
    Abstract: To provide a method for producing an oyster meat essence that more amply incorporates an antioxidant substance with high ORAC value as follows. A portion of an oyster meat extract more amply incorporating an antioxidant substance with high ORAC value is selected. An extraction method that allows incorporating further large amount of antioxidant substance with high ORAC value is employed. The beneficial oyster meat extract can be efficiently extracted in large amounts. Object An oyster meat is stored in an extraction container where water is accumulated. An oyster meat essence is extracted to generate an extract liquid. The extract liquid is injected to a centrifuge, and concurrently the centrifuge is rotated at a centrifugal acceleration where an antioxidant substance with high antioxidative potency and ORAC value is separated and removed from the extract liquid. The antioxidant substance with higher antioxidative potency and ORAC value is separated.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: April 25, 2017
    Assignee: Watanable Oyster Laboratory Co., Ltd.
    Inventors: Mitsugu Watanabe, Takayuki Watanabe, Hideaki Watanabe
  • Patent number: 9566369
    Abstract: A method for producing sterile, decellurized bioprosthetic tissue comprising: (a) contacting a human tissue with a hypotonic solution to produce a lysed tissue, (b) contacting the lysed tissue with a first surfactant to produce a surfactant-treated tissue, (c) contacting the surfactant-treated tissue with a nuclease enzyme solution to produce an enzyme-treated tissue, (d) contacting the enzyme-treated tissue with a cleaning solution comprising a second surfactant, a chaotropic agent or a mixture thereof to produce a decellurized tissue and (e) contacting the decellurized tissue with a bioburden reducing agent to produce the final bioprosthetic tissue. Kits to be used in conjunction with said method, as well as, the bioprosthetic tissue produced via said method are also provided.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: February 14, 2017
    Assignee: DECELL TECHNOLOGIES INC.
    Inventor: Paul F. Gratzer
  • Patent number: 9555116
    Abstract: The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolyzed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment of prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 31, 2017
    Inventor: Michael Anthony Folan
  • Patent number: 9511098
    Abstract: A method for producing dry earthworm powder, by which dry earthworm powder having high-titer enzymes can be produced while removing toxic substances contained in the bodies of earthworms, is provided. The method comprises: contacting a live earthworm with a chloride(s) of at least one metal selected from the group consisting of potassium, sodium, magnesium and calcium; and subsequently contacting the live earthworm with powder of a hydroxycarboxylic acid(s) and diluting the resulting mixture with water to adjust pH to 2 to 5, followed by leaving the live earthworm to stand for 3 to 180 minutes, washing the live earthworm with water, grinding the washed live earthworm and freeze-drying the obtained ground product.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: December 6, 2016
    Assignee: WELL STONE CO.
    Inventor: Kazuyuki Ishii
  • Patent number: 9474829
    Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: October 25, 2016
    Assignee: ACell, Inc.
    Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
  • Patent number: 9383358
    Abstract: The invention is directed to a method to establish a biologically significant association of gene expression levels among two or more genes, the method comprising assaying a sample for expression levels of two or more genes and identifying statistically-significant associations using a correlation coefficient in the range of about 0.6 to about 1.0, wherein a correlation coefficient in that range signifies a biologically significant correlation.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 5, 2016
    Assignee: CellPrint IP Holding, LLC
    Inventor: David R. Kaplan
  • Patent number: 9265804
    Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 23, 2016
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • Patent number: 9259444
    Abstract: The subject of the present invention is a bioactive cell homogenate produced from cells belonging to the MIC-1 stem cell line derived from growing deer antlers (Cervidae) deposited at the DSMZ under the accession DSM ACC2854, a method of producing and using it. The present invention also encompasses a pharmaceutical or cosmetic composition containing the above-mentioned homogenate.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: February 16, 2016
    Assignee: STEM CELLS SPIN S.A.
    Inventors: Wojciech Dziewiszek, Marek Cegielski, Marek Bochnia
  • Patent number: 9211307
    Abstract: Compositions containing acellularized biomaterial derived from differentiating pluripotent cells, for example, embryonic stem cells are provided. The acellularized biomaterial can be used to promote wound healing, promote tissue regeneration, or inhibit scarring. Methods for using the acellularized biomaterial for treating degenerative diseases are also provided.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: December 15, 2015
    Assignee: Georgia Tech Research Corporation
    Inventors: Todd Christopher McDevitt, Rehka Ramachandran Nair
  • Patent number: 9157840
    Abstract: The present inventive concept provides a multiple separation device and a method of separating a blood cancer cell using the same. In the device and the method, a blood sample is put in a fine channel and then cancer cells can be separated according to the type of cancer by controlling a flow velocity of the blood or a magnetic force of ferromagnetic pattern.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: October 13, 2015
    Assignee: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Seong-Mok Cho, Dae-Sik Lee, Jeong Won Park, Moon Youn Jung
  • Publication number: 20150140112
    Abstract: The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.
    Type: Application
    Filed: October 31, 2012
    Publication date: May 21, 2015
    Inventors: Beyong Dae Choi, Seong Hun Jeong, Shi Hyang Park, Myung Sook Kim, Soon Ok Choi
  • Patent number: 9034585
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: Health Diagnostic Laboratory, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9034335
    Abstract: The invention is in the field of therapeutic treatment of tumors. It has been found that the conditioned medium resulting from culturing an adult stem cell capable of differentiating into a plurality of differentiated cell types in a liquid cell culture medium and/or the adult stem cell from which the conditioned medium is obtainable, exert a remarkable anti-tumor effect. The adult stem cell derived conditioned medium preferred in this therapeutic application is a cell free conditioned medium derived from a human liver stem cell (HLSC).
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: May 19, 2015
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Patent number: 9034388
    Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: May 19, 2015
    Assignee: AKER BIOMARINE ANTARTIC AS
    Inventors: Inge Bruheim, Mikko Griinari, Snorre Tilseth, Sebastiano Banni, Jeffrey Stuart Cohn, Daniele Mancinelli
  • Publication number: 20150132401
    Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 14, 2015
    Applicant: ELC Management, LLC
    Inventors: Donald F. Collins, Daniel M. Maes, Neelam Muizzuddin
  • Patent number: 9028877
    Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: May 12, 2015
    Assignee: Aker Biomarine Antarctic AS
    Inventors: Inge Bruheim, Snorre Tilseth, Daniele Mancinelli
  • Patent number: 9023379
    Abstract: Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: May 5, 2015
    Assignee: Pathak Holdings LLC
    Inventors: Chandrashekhar P. Pathak, Sanjay M. Thigle
  • Publication number: 20150118200
    Abstract: Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products.
    Type: Application
    Filed: December 24, 2014
    Publication date: April 30, 2015
    Inventors: Ilene SUGINO, Vamsi GULLAPALLI, Marco ZARBIN
  • Publication number: 20150104522
    Abstract: This invention relates to use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule, based on the total weight of the pharmaceutical compositions. In the sesame oil extract, each of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule is in an amount of 2 to 10% by weight of dry raw material based on the total weight of sesame oil. This invention also relates to a medical dressing for treating diabetic ulcer and corresponding medicine box enclosing the said dressing.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventor: Rongxiang XU
  • Patent number: 8993250
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: March 31, 2015
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
  • Publication number: 20150079190
    Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Applicant: STEMNION, INC.
    Inventors: Randall G. Rupp, Linda O. Palladino
  • Publication number: 20150064269
    Abstract: [Task] A method for producing dry earthworm powder, in which there is no risk of reduction of the enzymatic activity of earthworms and the enzymatic activity of the dry earthworm powder obtained therefrom is increased, is provided. [Means for Resolution] Disclosed is a method for producing dry earthworm powder, in which earthworms which have been subjected to a treatment for removing casting soil are used as a raw material to produce dry earthworm powder, the living organisms of the earthworms or crushed products thereof which have been subjected to a treatment for removing casting soil are subjected to a pressurization treatment under a pressure condition of 10 MPa to 500 MPa and a temperature condition of 0° C. to 70° C., and the earthworms or crushed products thereof after the pressurization treatment are used as a raw material of the dry earthworm powder.
    Type: Application
    Filed: August 22, 2014
    Publication date: March 5, 2015
    Applicants: WAKI PHARMACEUTICAL CO., LTD., NATIONAL INSTITUTE OF TECHNOLOGY
    Inventors: Shin-ichi AKAZAWA, Shinnosuke WAKIMOTO, Toshinori WATANABE
  • Patent number: 8969017
    Abstract: The present invention provides methods for differentiating a pediatric subject with pediatric septic shock from a healthy pediatric subject or one having sudden inflammatory response syndrome (SIRS). Also provided is a method of predicting pediatric septic shock mortality in a pediatric septic shock patient.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: March 3, 2015
    Assignees: UTI Limited Partnership, Children's Hospital Medical Center
    Inventors: Beata Mickiewicz, Hans J. Vogel, Hector R. Wong, Brent W. Winston